id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-279765-sb1ifyfx	Isakova-Sivak, Irina	A promising inactivated whole-virion SARS-CoV-2 vaccine	2020-10-15		.txt	text/plain	1083	52	44	In this regard, the study by Shengli Xia and colleagues 7 is timely because it provides valuable evidence for the safety and immunogenicity of a β-propiolactone inactivated aluminium hydroxideadjuvanted whole-virion SARS-CoV-2 vaccine candidate developed by China National Biotec Group and the Beijing Institute of Biological Products (BBIBP-CorV), which was tested in randomised, double-blind, placebocontrolled phase 1/2 clinical trials in healthy individuals aged 18 years and older. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	./cache/cord-279765-sb1ifyfx.txt	./txt/cord-279765-sb1ifyfx.txt